Sterling Infrastructure (STRL - Free Report) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.
Over the past month, shares of this civil construction company have returned +8%, compared to the Zacks S&P 500 composite's +4.6% change. During this period, the Zacks Engineering - R and D Services industry, which Sterling Infrastructure falls in, has gained 2.6%. The key question now is: What could be the stock's future direction?
While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to an immediate price change, there are always some fundamental facts that eventually dominate the buy-and-hold decision-making.
Revisions to Earnings EstimatesHere at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock.
We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For the current quarter, Sterling Infrastructure is expected to post earnings of $4.70 per share, indicating a change of +74.7% from the year-ago quarter. The Zacks Consensus Estimate has changed +31.9% over the last 30 days.
For the current fiscal year, the consensus earnings estimate of $17.95 points to a change of +65% from the prior year. Over the last 30 days, this estimate has changed +0.4%.
For the next fiscal year, the consensus earnings estimate of $23.07 indicates a change of +28.5% from what Sterling Infrastructure is expected to report a year ago. Over the past month, the estimate has changed +44.4%.
Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Sterling Infrastructure is rated Zacks Rank #1 (Strong Buy).
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
12 Month EPS
Projected Revenue GrowthEven though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.
For Sterling Infrastructure, the consensus sales estimate for the current quarter of $942.18 million indicates a year-over-year change of +53.3%. For the current and next fiscal years, $3.69 billion and $4.39 billion estimates indicate +48% and +19% changes, respectively.
Last Reported Results and Surprise HistorySterling Infrastructure reported revenues of $825.67 million in the last reported quarter, representing a year-over-year change of +91.6%. EPS of $3.59 for the same period compares with $1.63 a year ago.
Compared to the Zacks Consensus Estimate of $585.36 million, the reported revenues represent a surprise of +41.05%. The EPS surprise was +56.77%.
The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates each time over this period.
ValuationWithout considering a stock's valuation, no investment decision can be efficient. In predicting a stock's future price performance, it's crucial to determine whether its current price correctly reflects the intrinsic value of the underlying business and the company's growth prospects.
Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.
As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
Sterling Infrastructure is graded F on this front, indicating that it is trading at a premium to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
Bottom LineThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Sterling Infrastructure. However, its Zacks Rank #1 does suggest that it may outperform the broader market in the near term.
Sterling Infrastructure has transformed into an E-Infrastructure leader, capitalizing on AI-driven data center and semiconductor facility demand. In Q1 2026, STRL posted 92% YoY revenue growth to $825.7M, with E-Infrastructure contributing 60% of FY25 revenue and driving record backlogs. STRL trades at a significant premium (75.56x P/E TTM), justified by triple-digit E-Infrastructure growth, expanding backlogs, and a forward PEG of 1.35x.
Key Takeaways STRL won a $500M first phase of a multi-year semiconductor fab campus via a JV.Sterling expects phase one to wrap in late 2027 or early 2028, with decades of follow-on work.STRL's E-Infrastructure revenue jumped 174% YoY, with mission-critical work topping 90% of backlog. Sterling Infrastructure (STRL - Free Report) is increasingly positioning itself to benefit from America’s growing semiconductor manufacturing investment wave. While the company has built its recent success around data-center infrastructure, management now sees semiconductor fabrication facilities as a significant long-term growth opportunity that could complement its already fast-growing E-Infrastructure business.
The most notable development came in the first quarter of 2026, when Sterling secured the initial phase of site-development work for a large multi-year semiconductor fabrication campus. Management disclosed that the first phase exceeds $500 million and will be executed through a joint venture, with completion expected in late 2027 or early 2028. Importantly, the broader campus is expected to be developed over multiple decades, creating opportunities for additional work well beyond the initial phase.
Sterling believes its expertise in large-scale site development, gained through years of executing complex data-center projects, provides a competitive advantage in semiconductor facilities. During the earnings call, management highlighted that the company’s capabilities differentiated it from competitors and helped secure what it described as one of the largest semiconductor fabrication projects currently planned in the United States.
The opportunity arrives as Sterling’s E-Infrastructure segment continues to accelerate. First-quarter E-Infrastructure revenues surged 174% year over year, while mission-critical projects, including data centers, manufacturing facilities and semiconductor projects, represented more than 90% of segment backlog.
Management believes broader semiconductor-fab activity in the United States could accelerate toward the end of the decade, potentially opening a new avenue of growth alongside data centers. Combined with a record backlog, expanding future-phase opportunities and raised 2026 guidance, Sterling’s early semiconductor success could become an important long-term growth engine for the company.
How Sterling Compares With Key Infrastructure RivalsSterling operates in highly attractive end markets such as data centers, advanced manufacturing and semiconductor facilities, but it is not alone in pursuing these opportunities. Two notable competitors are EMCOR Group (EME - Free Report) and Quanta Services (PWR - Free Report) .
EMCOR has built a strong position in mission-critical construction and electrical services. The company benefits from rising investments in data centers, industrial facilities and technology infrastructure. Like Sterling, EMCOR is leveraging the growing demand for complex projects that require specialized engineering and construction expertise.
However, EMCOR remains more diversified across mechanical and electrical contracting, whereas Sterling is increasingly emphasizing large-scale site development tied to data centers and semiconductor campuses. As semiconductor investments expand, EMCOR is likely to remain a significant competitor for related infrastructure work. EMCOR’s extensive customer relationships and nationwide footprint further strengthen its competitive position.
Quanta is another major infrastructure player benefiting from long-term capital spending trends. The company has deep expertise in power, utility and industrial infrastructure, areas that are becoming increasingly important as semiconductor fabs and AI-driven data centers require massive power capacity. Quanta is also expanding its exposure to advanced manufacturing projects, placing it in direct competition with Sterling for certain large-scale developments.
While Quanta possesses broader utility and energy capabilities, Sterling’s specialized site-development expertise could help it carve out a differentiated position in the emerging semiconductor construction market. Quanta remains one of the most formidable competitors in this rapidly growing infrastructure space.
STRL Stock’s Price Performance & Valuation TrendShares of this Texas-based infrastructure services provider have gained 188.1% year to date, outperforming the Zacks Engineering - R and D Services industry, the broader Construction sector and the S&P 500 Index.
STRL Price Performance (YTD)
Image Source: Zacks Investment Research
STRL stock is currently trading at a premium compared with its industry peers, with a forward 12-month price-to-earnings (P/E) ratio of 43.73, as shown in the chart below.
STRL's P/E Ratio (Forward 12-Month) vs. Industry
Image Source: Zacks Investment Research
Earnings Estimate Revision of STRL
STRL’s earnings estimates for 2026 and 2027 have moved upward in the past 30 days to $17.95 and $23.07 per share, respectively, as shown below. The revised estimates for 2026 and 2027 imply year-over-year growth of 65% and 28.5%, respectively.
Image Source: Zacks Investment Research
Sterling currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Acquisition Expands Sterling's E-Infrastructure Site Development Services Into the Pacific Northwest
, /PRNewswire/ -- Sterling Infrastructure, Inc. (NasdaqGS: STRL) ("Sterling" or "the Company") today announced that it has closed on the acquisition of Stone Ridge Contracting, LLC. (Stone Ridge), a Pocatello, Idaho-based site development contractor. Stone Ridge will join Sterling's E-Infrastructure Solutions segment.
Stone Ridge is a leading, non-union contractor delivering heavy civil, concrete, and construction management services across high-growth sectors including data centers, mining, and industrial infrastructure. The transaction strengthens Sterling's E-Infrastructure geographic footprint across the Pacific Northwest and Texas, which have been key focus areas for strategic geographic expansion. The Stone Ridge service area includes Idaho, Oregon, North Dakota, Washington, and Texas.
Stone Ridge is expected to generate full-year 2026 revenue in the range of $180 million to $200 million and EBITDA margins in the mid-teens, consistent with well-run site development contractors of similar scale. Sterling plans to update its full year 2026 financial guidance to reflect the partial year contribution from Stone Ridge at the time of its second quarter 2026 financial report.
The purchase price multiple paid for Stone Ridge is within Sterling's typical range for site development assets. The upfront purchase price consists of a combination of cash and Sterling common stock. Additionally, Stone Ridge has an earn out opportunity, contingent upon meeting certain EBITDA targets on or before December 31, 2031.
Management Commentary
"We are excited to welcome Stone Ridge to the Sterling family. The team at Stone Ridge has built an exceptional company through a relentless focus on customers, operational excellence, and entrepreneurial leadership," stated Joe Cutillo, Sterling's Chief Executive Officer. "Just as important, they share Sterling's culture and long-term approach to creating value. We are pleased that the leadership team will remain in place following the transaction to guide the business through its next chapter of growth."
"This acquisition strengthens our ability to serve existing customers across a broader geographic footprint while also adding new, attractive end markets and customer relationships," continued Mr. Cutillo. "Further, we believe that by leveraging Sterling's broad platform and financial resources, there is a compelling opportunity to accelerate growth and drive margin expansion at Stone Ridge. We look forward to building on the strong foundation already in place and capitalizing on the significant opportunities ahead."
About Sterling
Sterling Infrastructure, Inc., ("Sterling," "the Company," "we," "our" or "us") operates through a variety of subsidiaries within three segments specializing in E-Infrastructure, Transportation and Building Solutions in the United States, primarily across the Southern, Northeastern, Mid-Atlantic and Rocky Mountain regions and the Pacific Islands. E-Infrastructure Solutions provides advanced, large-scale site development services and mission-critical electrical services for data centers, semiconductor fabrication, manufacturing, distribution centers, warehousing, power generation and more. Transportation Solutions includes infrastructure and rehabilitation projects for highways, roads, bridges, airports, ports, rail and storm drainage systems. Building Solutions includes residential and commercial concrete foundations for single-family and multi-family homes, parking structures, elevated slabs, other concrete work, plumbing services, and surveys for new single-family residential builds. From strategy to operations, we are committed to sustainability by operating responsibly to safeguard and improve society's quality of life. Caring for our people and our communities, our customers and our investors – that is The Sterling Way.
Joe Cutillo, CEO, "We build and service the infrastructure that enables our economy to run,
our people to move and our country to grow."
Company Contact:
Sterling Infrastructure, Inc.
Noelle Dilts, VP of Investor Relations and Corporate Strategy
281-214-0795
[email protected]
Key Takeaways Sterling's backlog reached $5.15B, with over 90% of E-Infrastructure work tied to mission-critical projects.Raised 2026 view reflects strong demand from AI data centers, semiconductors and advanced manufacturing.STRL trades at a premium valuation, with a forward 12-month P/E ratio of 44.16, compared with its peers. Sterling Infrastructure, Inc. (STRL - Free Report) stock surged 191.2% in the year-to-date period, significantly outperforming the Zacks Engineering - R and D Services industry, the broader Zacks Construction sector and the S&P 500 Index.
This Texas-based infrastructure services provider started its 2026 journey with phenomenal financial performance amid favorable market trends, with multi-year demand growth visibility. As mission-critical activity in data centers, advanced manufacturing and semiconductors grows, it is creating numerous project opportunities for the company, stabilizing its market footing and prospects in the upcoming term.
Moreover, STRL’s strategic business efforts, organic or inorganic, alongside its commitment to enhance shareholder value, create a striking impression on investors even during a turbulent global macroeconomic scenario.
Image Source: Zacks Investment Research
Let’s dive deep into understanding the factors backing STRL stock’s prospects in the upcoming period.
AI Infrastructure Boom Drives Backlog ExpansionSterling is riding powerful secular tailwinds from surging investments in AI data centers, semiconductor fabs and advanced manufacturing facilities. The company ended first-quarter 2026 with a record $3.8 billion signed backlog and $5.15 billion combined backlog, representing year-over-year growth of 78% and 131%, respectively. Adding to this strength, STRL’s pipeline of high-probability future phase opportunities now exceeds $1.3 billion, bringing its visible work pool close to $6.5 billion. With more than 90% of E-Infrastructure backlog tied to mission-critical projects, the company enjoys strong demand visibility and is well-positioned to capitalize on the ongoing AI infrastructure buildout.
Besides, STRL’s acquired CEC business has secured several large project awards since then. Management noted these wins contributed to a $1.2 billion increase in CEC’s combined backlog. The awards reflect traction in CEC’s mission-critical electrical services and broaden the volume of secured work feeding future revenues. Notably, a first-phase award for a mega-fab campus, expected to run through late 2027 or early 2028, adds duration and line of sight, while the broader U.S. semiconductor wave is expected to accelerate near decade-end (2029-2030). This depth and duration of demand support sustained revenue conversion and pricing discipline beyond 2026 for Sterling.
Integrated Service Model Strengthens Competitive AdvantageSterling's acquisition of CEC has enhanced its ability to offer integrated site development and mission-critical electrical services under one roof. The company is already executing projects where both capabilities are being delivered together, creating cross-selling opportunities and deeper customer relationships. This strategy improves project coordination, execution efficiency and margin potential while making Sterling a more valuable partner for hyperscale data center and semiconductor customers. The integrated approach also differentiates Sterling from traditional contractors and increases its ability to secure larger, multi-phase infrastructure awards.
Raised 2026 Outlook Reflects Strong Long-Term VisibilityFollowing a record first quarter of 2026, management raised its full-year 2026 guidance, signaling confidence in future demand and execution capabilities. Sterling now expects revenues of $3.7-$3.8 billion and adjusted EPS of $18.40-$19.05, implying approximately 51% revenue growth and 72% earnings growth year over year at the midpoint. Strong bid activity, expanding backlog and increasing exposure to high-growth AI and semiconductor markets provide a solid foundation for sustained expansion. The company's growing presence across mission-critical infrastructure positions it to benefit from multiyear investment cycles and long-term industry growth trends. STRL also lifted adjusted EBITDA to $843-$873 million compared with its earlier adjusted EBITDA forecast of $626-$659 million.
Earnings Growth and Shareholder-Friendly Capital AllocationSterling continues to deliver exceptional profitability and cash generation. First-quarter 2026 adjusted net income jumped 122% year over year, while adjusted EBITDA increased 107%, supported by strong execution and a favorable project mix. Operating cash flow nearly doubled to $166 million, strengthening an already healthy balance sheet with more than $500 million in cash. Alongside investing in growth opportunities, Sterling remains committed to enhancing shareholder value through disciplined capital deployment. The company repurchased $12.3 million of shares during the first quarter, reflecting management's confidence in the business and its long-term earnings potential.
STRL retains $362 million of share repurchase authorization and intends to be opportunistic after the first quarter’s buyback. Management also notes a richer pipeline of high-quality M&A targets compared with a year ago and cites significant balance sheet firepower. This setup supports selective acquisitions, internal capacity adds and buybacks without stressing leverage, helping cushion timing variability as backlog converts.
Earnings Estimate Revision for STRLSTRL’s earnings estimates for 2026 and 2027 have moved upward in the past 30 days to $17.95 and $23.07 per share, respectively. The estimated figures for 2026 and 2027 imply year-over-year growth of 65% and 28.5%, respectively.
Image Source: Zacks Investment Research
Is Sterling Winning the Backlog Battle Against Its Peers?Sterling Infrastructure is emerging as a fast-growing beneficiary of the AI infrastructure boom, competing with industry leaders such as EMCOR Group, Inc. (EME - Free Report) , MasTec, Inc. (MTZ - Free Report) and Quanta Services, Inc. (PWR - Free Report) . STRL’s combined backlog surged 131% year over year to $5.15 billion in first-quarter 2026, supported by major data center and semiconductor awards. The company is also gaining traction in AI-related projects through its integrated site-development and electrical-services platform following the CEC acquisition.
EMCOR continues to benefit from mission-critical mechanical and electrical work tied to data centers, while MasTec is leveraging its engineering and construction expertise to secure data center deployment opportunities. Quanta remains the largest player, capitalizing on AI-driven power demand, grid modernization and utility-scale infrastructure projects with a substantially larger backlog and customer base.
Sterling's competitive advantage lies in its faster growth rate, strong backlog momentum and unique ability to combine large-scale site development with mission-critical electrical services. However, Quanta retains a scale advantage, while EMCOR and MasTec possess broader diversification. STRL’s edge is execution and growth; its peers still lead in size and market reach.
STRL Stock Trading at a PremiumSTRL stock is currently trading at a premium compared with its industry peers, with a forward 12-month price-to-earnings (P/E) ratio of 44.16, as shown in the chart below.
Image Source: Zacks Investment Research
Is It Wise to Invest in STRL Stock Now?As discussed above, Sterling continues to present a compelling long-term growth story supported by powerful secular trends in AI infrastructure, data centers, semiconductor manufacturing and advanced industrial construction. Its competitive position has strengthened considerably following the CEC acquisition, which enables it to offer integrated site development and mission-critical electrical services. A growing pipeline of future opportunities and strong exposure to multiyear AI-related investments provide exceptional revenue visibility through 2027 and beyond.
Financially, STRL remains in excellent shape. Triple-digit growth in adjusted earnings and EBITDA, robust operating cash flow generation, a sizeable cash position and ongoing share repurchases highlight management’s ability to create shareholder value while funding future expansion.
Meanwhile, the valuation remains a concern, as STRL commands a significant premium to peers after its massive 191.2% stock run. While the premium appears justified by its superior growth profile, near-term volatility or profit-taking cannot be ruled out.
Thus, with rising earnings estimates and exceptional backlog momentum, STRL stock, which currently sports a Zacks Rank #1 (Strong Buy), is a strategic buy option for mid and long-term investors. However, investors with shorter investment horizons may consider accumulating shares gradually or waiting for market-driven pullbacks to secure a more attractive entry point. You can see the complete list of today’s Zacks #1 Rank stocks here.
Sterling Infrastructure (STRL - Free Report) closed at $842.39 in the latest trading session, marking a -5.55% move from the prior day. This change lagged the S&P 500's daily loss of 0.26%. Elsewhere, the Dow gained 0.17%, while the tech-heavy Nasdaq lost 0.97%.
The stock of civil construction company has risen by 2.73% in the past month, leading the Construction sector's loss of 2.63% and the S&P 500's gain of 0.23%.
The upcoming earnings release of Sterling Infrastructure will be of great interest to investors. The company is forecasted to report an EPS of $4.7, showcasing a 74.72% upward movement from the corresponding quarter of the prior year. At the same time, our most recent consensus estimate is projecting a revenue of $970.26 million, reflecting a 57.9% rise from the equivalent quarter last year.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $17.95 per share and a revenue of $3.8 billion, representing changes of +64.98% and +52.48%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for Sterling Infrastructure. These recent revisions tend to reflect the evolving nature of short-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Within the past 30 days, our consensus EPS projection has moved 0.09% higher. Sterling Infrastructure is currently sporting a Zacks Rank of #1 (Strong Buy).
Valuation is also important, so investors should note that Sterling Infrastructure has a Forward P/E ratio of 49.68 right now. Its industry sports an average Forward P/E of 33.33, so one might conclude that Sterling Infrastructure is trading at a premium comparatively.
Investors should also note that STRL has a PEG ratio of 3.31 right now. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Engineering - R and D Services industry had an average PEG ratio of 1.92 as trading concluded yesterday.
The Engineering - R and D Services industry is part of the Construction sector. Currently, this industry holds a Zacks Industry Rank of 73, positioning it in the top 30% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
Key Takeaways Sterling acquired Stone Ridge, expanding its presence across Idaho, Oregon, Washington, Texas and beyond.Stone Ridge is expected to generate $180M-$200M in 2026 revenues with mid-teens EBITDA margins.STRL's acquisition strategy boosts integrated infrastructure capabilities and supports backlog growth. Sterling Infrastructure, Inc. (STRL - Free Report) has expanded its geographic footprint in the Pacific Northwest and Texas by acquiring Stone Ridge Contracting, LLC. The acquired company will be operating under STRL’s E-Infrastructure Solutions segment.
Sterling stock tumbled 5.6% during yesterday’s trading hours and moved further down 2% in the after-hours.
Sterling’s Growth Momentum With Stone Ridge DealStone Ridge is a Pocatello, ID-based heavy civil, concrete and construction management services provider that strengthens STRL’s hold on high-growth markets of Idaho, Oregon, North Dakota, Washington and Texas. The services of Stone Ridge stretch across booming sectors, including data centers, mining and industrial infrastructure.
Notably, in 2026, Stone Ridge is expected to generate revenues between $180 million and $200 million, with EBITDA margins projected to be in the mid-teens. Sterling will be reporting its updated 2026 guidance in the second-quarter 2026 financial reports, highlighting the partial-year contributions from the Stone Ridge acquisition.
The purchase price includes a combination of cash and Sterling common stock, with Stone Ridge having an earn-out opportunity, contingent upon meeting certain EBITDA targets on or before Dec. 31, 2031.
STRL’s Buyout Efforts Bode WellSterling’s acquisition strategy is evolving beyond simple scale expansion and is increasingly becoming a competitive differentiator. The acquisition of CEC has significantly strengthened Sterling’s presence in high-growth, mission-critical markets such as AI-driven data centers, semiconductor fabrication facilities and advanced manufacturing projects. In the first quarter of 2026 alone, CEC contributed $156 million in revenues and nearly $1.9 billion to the combined backlog, accelerating Sterling’s growth trajectory and enhancing earnings visibility.
More importantly, the deal enables STRL to offer integrated site-development and electrical-services solutions, creating cross-selling opportunities and positioning the company as a one-stop partner for complex infrastructure projects. This integrated model is already generating results, with the company executing data center campuses that combine both capabilities.
Moreover, Sterling’s strong balance sheet provides ample flexibility to pursue further strategic acquisitions while continuing to invest in organic growth initiatives. It ended the first quarter of 2026 with $511.9 million in cash and cash equivalents, generated a robust operating cash flow of $165.6 million and maintained a manageable debt profile. This financial strength enables Sterling to fund acquisitions without overleveraging the balance sheet, while also supporting capital expenditures, share repurchases and future expansion opportunities.
STRL Stock’s Price PerformanceShares of this Texas-based infrastructure services provider soared 174.9% year to date, significantly outperforming the Zacks Engineering - R and D Services industry, the broader Construction sector and the S&P 500 Index.
Image Source: Zacks Investment Research
Besides contributions from its strategic acquisitions, STRL is gaining from multi-year growth visibility for mission-critical activities, alongside its ability to offer integrated site development and mission-critical electrical services under one roof.
Sterling’s Zacks Rank & Other Key PicksSterling currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Here are some other top-ranked stocks from the same sector.
Comfort Systems USA, Inc. (FIX - Free Report) currently sports a Zacks Rank of 1. Comfort Systems delivered a trailing four-quarter earnings surprise of 39.3%, on average. The stock has surged 96.2% year to date.
The Zacks Consensus Estimate for Comfort Systems’ 2026 sales and earnings per share (EPS) indicates improvements of 30.5% and 49.1%, respectively, from a year ago.
Quanta Services, Inc. (PWR - Free Report) currently sports a Zacks Rank of 1. Quanta delivered a trailing four-quarter earnings surprise of 10.3%, on average. The stock has climbed 63.9% year to date.
The Zacks Consensus Estimate for Quanta’s 2026 sales and EPS implies an increase of 21.5% and 29.7%, respectively, from a year ago.
Dycom Industries, Inc. (DY - Free Report) presently sports a Zacks Rank of 1. It has a trailing four-quarter earnings surprise of 25%, on average. Shares of Dycom have increased 34.3% year to date.
The Zacks Consensus Estimate for Dycom’s fiscal 2027 sales and EPS indicates growth of 34.8% and 30.3%, respectively, from the prior-year levels.
Biocorrx (OTCMKTS:BICX - Get Free Report) and GoodRx (NASDAQ: GDRX - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability. Profitability This table compares Biocorrx and GoodRx's net margins,
Nutex Health (NASDAQ: NUTX - Get Free Report) and GoodRx (NASDAQ: GDRX - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, dividends, profitability and analyst recommendations. Profitability This table compares Nutex Health and GoodRx's
SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for prescription savings in the U.S., today announced that it is working with Eli Lilly and Company to expand access to the newly FDA-approved oral GLP-1 medication, Foundayo™ (orforglipron). Eligible self-pay patients can access Foundayo through GoodRx at a starting price of $149 per month, in line with the lowest available discounted cash price at launch. The offering provides transparent pricing and nationwide.
SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for prescription savings in the U.S., today announced that the new higher dose Wegovy® HD (semaglutide) injection 7.2 mg is now available to eligible self-pay patients on GoodRx at $399 per month. Pricing scales with quantity, with a two-month supply available for $798 and a three-month supply available for $1,197, giving consumers flexibility and clear expectations around cost. For patients, Wegovy HD offers an.
This move comes amid a growing demand for GLP-1 treatments, which reflects GoodRx’s ongoing efforts to simplify access to medications.
GoodRx is a platform for medication savings in the U.S., used by nearly 25 million consumers and over one million healthcare professionals annually.
In March, the U.S. Food and Drug Administration (FDA) approved a higher-dose version of Wegovy, marking an expansion of its treatment portfolio for adults with obesity.
Tiered Pricing Structure Offers FlexibilityPricing scales with quantity, with a two-month supply available for $798 and a three-month supply available for $1,197, giving consumers flexibility and clear expectations around cost.
For patients, Wegovy HD offers an additional FDA-approved step-up option within the Wegovy portfolio, potentially helping eligible patients achieve greater weight-loss benefit without requiring them to switch to a different brand or care pathway.
GoodRx announced that the new Wegovy HD injection is now available to eligible self-pay patients, with pricing options scaling for multiple-month supplies.
Last week, GoodRx revealed that it is expanding access to Eli Lilly and Company's (NYSE:LLY) new oral GLP-1 medication, Foundayo.
GoodRx announced that eligible self-pay consumers can access Foundayo starting at $149 per month.
The company is also expanding access to Zepbound, available to eligible self-pay patients starting at $299 per month at more than 70,000 pharmacies nationwide.
Technical Indicators Show Short-Term StrengthGoodRx’s relative strength index (RSI) is at 56.74, which indicates neutral momentum, suggesting the stock is not currently overbought or oversold.
Additionally, the moving average convergence divergence (MACD) is above its signal line, indicating bullish momentum, which may attract buyers looking for upward movement.
Key Resistance: $2.50 — A level where selling pressure may increase. Key Support: $2 — A level where buying interest may emerge. Analyst Consensus & Recent Actions: The stock carries a Hold rating with an average price target of $3.73. Recent analyst moves include:
Wells Fargo: Overweight (Lowers target to $3.50 on March 4) Citigroup: Buy (Lowers target to $3.50 on March 3) Goldman Sachs: Neutral (Lowers target to $2.50 on March 2) GDRX Stock Price Activity: GoodRx Holdings shares were up 2.69% at $2.29 at the time of publication on Wednesday, according to Benzinga Pro data.
Image via Shutterstock
This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Market News and Data brought to you by Benzinga APIs
SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), the leading platform for prescription savings in the U.S., today announced it will release its first quarter 2026 financial results after U.S. markets close on Wednesday, May 6, 2026. GoodRx management will also hold a conference call and webcast the following morning, Thursday, May 7, 2026 at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's business o.
Key Takeaways OptimizeRx gains from strong adoption of its AI-enabled DAAP, driving scalable pharma engagement.OPRX faces near-term revenue pressure from cautious pharma spending and a shift away from managed services.GoodRx sees solid prescription volume but struggles with pricing pressure and softer telehealth growth. OptimizeRx Corporation (OPRX - Free Report) and GoodRx Holdings, Inc. (GDRX - Free Report) operate in the digital health ecosystem, offering technology-driven solutions that connect stakeholders across healthcare and pharmaceuticals. OptimizeRx serves as a partner to life sciences companies through its proprietary communications network and omnichannel platform, enabling targeted, data-driven engagement at the point of care, including its artificial intelligence (AI)-enabled Dynamic Audience Activation Platform (DAAP) for precise provider interactions.
GoodRx focuses on improving prescription access and affordability through its large-scale consumer platform, offering direct-to-consumer programs, integrated savings and a leading app, while expanding into pharma manufacturer solutions and supporting a more transparent and seamless prescription journey.
Let’s evaluate their fundamentals, growth prospects, market challenges and valuations to determine which one presents a stronger investment opportunity.
The Case for OPRXOptimizeRx is gaining from the strong adoption of its AI-enabled DAAP, which is enabling precise and timely engagement for pharmaceutical customers at critical decision points. On the last earnings call, management indicated that validated performance is helping convert initial pilot programs into broader, scaled deployments across multiple brands, particularly in complex therapeutic areas such as oncology, supporting a more repeatable and durable growth trajectory.
Another key growth driver is increasing traction among mid-tier and long-tail life sciences companies, which management identified as a significant expansion opportunity. The platform’s ability to address core customer needs, such as improving workflow efficiency, enhancing engagement and connecting fragmented point-of-care systems, is strengthening its appeal and driving deeper penetration within this segment.
Momentum is also being supported by favorable AI trends, which management noted are not disrupting the business but instead acting as a potential tailwind. As customers achieve efficiencies in areas like content creation, they are expected to reallocate marketing resources toward solutions that expand reach and engagement, benefiting the company’s platform adoption and utilization. Additionally, the company benefits from its established communications network that links pharmaceutical manufacturers with healthcare providers, enabling targeted and measurable engagement.
Image Source: Zacks Investment Research
OptimizeRx is prioritizing margin stability and cash generation over aggressive expansion. It aims to sustain Rule of 40 performance, even in a challenging environment. OptimizeRx reiterated its focus on adjusted EBITDA, guiding $21-$25 million for 2026, higher than the previously estimated $19-$22 million. The company also anticipates a back-half-weighted performance, with stronger momentum expected later in the year as market conditions stabilize and customer spending trends improve.
However, the company is grappling with softness in contracted revenue, primarily due to a shift away from managed services, which had contributed meaningfully in the prior year. OptimizeRx expects 2026 revenues of $109-$114 million compared with the $118-$124 million provided at the end of the third quarter of 2025. Additionally, pharmaceutical clients are adopting a more cautious spending approach in early 2026 as they navigate most favored nation (MFN) pricing dynamics. This has led to shorter contract durations and a temporary pause in marketing spend across both direct-to-consumer and healthcare provider channels. These factors are expected to weigh on near-term growth, particularly in the first half of the year.
The Case for GDRXGoodRx is benefiting from steady growth in its prescription transactions platform, driven by strong consumer engagement and its ability to deliver price transparency and savings at scale. Expanding partnerships with pharmacies and pharmacy benefit managers (PBMs) are supporting consistent prescription volumes and reinforcing its role as a go-to platform for affordable medication access.
The company is also benefiting from momentum in its pharma manufacturer solutions and subscription offerings, as noted in the document, with increasing adoption of its integrated savings programs and direct-to-consumer solutions supporting revenue diversification, while ongoing enhancements to its platform and partnerships are enabling broader reach and improved user experience across its ecosystem.
GoodRx is facing headwinds from variability in prescription transaction revenues, with certain contractual dynamics and retail pharmacy relationships continuing to adversely impact pricing and margins, leading to pressure on revenue consistency despite stable user engagement levels.
GoodRx is also experiencing challenges related to declines in certain segments of its business, including softness in telehealth and subscription growth compared to prior periods, reflecting changing consumer behavior and a more competitive landscape affecting overall performance.
The company is dealing with ongoing margin pressures and investment requirements, with continued spending on technology, marketing and product innovation weighing on profitability, alongside external factors, such as industry pricing dynamics and partner negotiations contributing to uncertainty in near-term financial outcomes.
For 2026, the company expects revenues of $750-$780 million, implying a decline of 2-6% from $796.9 million reported in 2025. Adjusted EBITDA is expected to be at least $230 million, suggesting a 15% decline from the $270.5 million reported in 2025.
Share Performance for OPRX & GDRXIn the past year, OPRX stock has declined 25.9% while GDRX has plunged 50.8%.
Image Source: Zacks Investment Research
Valuation for OPRX & GDRXIn terms of Price/Book, OPRX shares are trading at 0.94X, lower than GDRX’s 1.28X.
Image Source: Zacks Investment Research
How Do Estimates Compare for OPRX & GDRX?Over the past 60 days, analysts have revised their estimates significantly upward for OPRX’s bottom line for the current year.
Image Source: Zacks Investment Research
For GDRX, estimates have been revised significantly downward over the past 60 days.
Image Source: Zacks Investment Research
OPRX or GDRX: Which Stock is the Better Investment?While OPRX has a Zacks Rank #1 (Strong Buy) at present, GDRX carries a Zacks Rank #4 (Sell). Consequently, in terms of Zacks Rank and valuation, OPRX seems to be a better option at the moment. You can see the complete list of today’s Zacks #1 Rank stocks here.
Key Takeaways Hims & Hers is moving care online with telehealth consults, digital prescriptions and home fulfillment.HIMS partnered with Novo Nordisk to offer FDA-approved GLP-1s in multiple formats at more affordable prices.HIMS added multi-cancer early detection testing and a Labs platform, while expanding into Canada and Europe. Hims & Hers Health, Inc. (HIMS - Free Report) is fundamentally built around expanding access to healthcare by shifting traditionally fragmented, in-person experiences into a more seamless digital model. Its platform connects consumers to licensed providers, enabling telehealth consultations, digital prescriptions and online fulfillment, all designed to make care faster, and more convenient and affordable. By integrating these capabilities, HIMS aims to reduce longstanding barriers such as stigma, cost and limited provider availability, while delivering personalized care across a wide range of conditions.
Recent developments reinforce this access-driven strategy. Hims & Hers has continued to broaden the availability of treatments by partnering with Novo Nordisk to offer FDA-approved GLP-1 medications at more affordable prices and through multiple delivery formats, simplifying access for eligible patients. At the same time, it has expanded proactive care through new offerings such as multi-cancer early detection testing and its Labs platform, both of which are designed to make advanced diagnostics more accessible and actionable for everyday consumers.
Geographic expansion has further extended this mission. Through acquisitions and market entries, Hims & Hers is scaling its digital-first model globally, including in Canada and Europe, with a focus on bringing affordable, personalized care to populations where access has historically been limited. Together, these initiatives reflect a consistent effort to democratize healthcare — making high-quality, personalized care more accessible across conditions, formats and geographies.
Hims & Hers is scheduled to report first-quarter 2026 results on May 11, after the closing bell.
GDRX and TDOC Expanding Digital Healthcare AccessGoodRx Holdings, Inc. (GDRX - Free Report) is advancing digital-first healthcare access by simplifying how consumers find, afford and receive treatments. GDRX has expanded condition-specific subscriptions, including services for hair loss and erectile dysfunction that combine virtual consultations, prescriptions and home delivery into a single streamlined experience, reducing barriers such as cost and inconvenience. At the same time, GoodRx continues to scale affordability through partnerships and pricing innovations. GoodRx enables access to high-cost therapies like GLP-1 treatments with transparent self-pay pricing, while also integrating savings directly at the pharmacy counter through programs like RxSmartSaver.
Teladoc Health, Inc. (TDOC - Free Report) is advancing digital-first healthcare access by delivering comprehensive virtual care across physical and mental health needs through its Integrated Care and BetterHelp platforms. Teladoc Health connects patients, providers and systems to enable 24/7 access to services spanning preventive, primary, chronic and mental healthcare, improving outcomes while lowering costs. Teladoc Health recently enhanced its 24/7 Care service to treat a broader range of conditions, integrate specialist input and streamline referrals, further expanding access and care continuity through its technology-driven ecosystem.
HIMS’ Price Performance, Valuation and EstimatesShares of Hims & Hers have lost 14.1% year to date compared with the industry’s decline of 21.8%.
Image Source: Zacks Investment Research
HIMS’ forward 12-month P/S of 2.1X is lower than the industry’s average of 3.4X and its five-year median of 2.6X. It has a Value Score of C.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for HIMS’ 2026 earnings per share suggests a 5.7% improvement compared with 2025.
Image Source: Zacks Investment Research
Hims & Hers currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for prescription savings in the U.S., today announced that it is providing access to self-pay pricing for Novo Nordisk's Ozempic® pill (oral semaglutide), helping eligible patients with type 2 diabetes obtain the medication for as low as $149 per month at pharmacies nationwide. “As Novo Nordisk brings the Ozempic pill to market, we're focused on helping patients access it with clear, transparent pricing,” said We.
SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," “GoodRx,” or the “Company”), the leading platform for medication savings in the U.S., has released its financial results for the first quarter of 2026. First Quarter 2026 Highlights Revenue of $194.0 million Net income of $1.2 million; Net income margin of 0.6% Adjusted Net Income1 of $23.0 million; Adjusted Net Income Margin1 of 11.9% Adjusted EBITDA1 of $58.3 million; Adjusted EBITDA Margin1 of 30.
GoodRx Holdings, Inc. (GDRX - Free Report) came out with quarterly earnings of $0.07 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.09 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -5.41%. A quarter ago, it was expected that this company would post earnings of $0.09 per share when it actually produced earnings of $0.09, delivering no surprise.
Over the last four quarters, the company has not been able to surpass consensus EPS estimates.
GoodRx, which belongs to the Zacks Medical Services industry, posted revenues of $194.01 million for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 7.73%. This compares to year-ago revenues of $202.97 million. The company has topped consensus revenue estimates three times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
GoodRx shares have lost about 5.5% since the beginning of the year versus the S&P 500's gain of 6%.
What's Next for GoodRx?While GoodRx has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for GoodRx was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.09 on $189.24 million in revenues for the coming quarter and $0.32 on $762.75 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical Services is currently in the top 39% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the same industry, Co-Diagnostics, Inc. (CODX - Free Report) , has yet to report results for the quarter ended March 2026. The results are expected to be released on May 14.
This company is expected to post quarterly loss of $3.60 per share in its upcoming report, which represents a year-over-year change of +50.1%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Co-Diagnostics, Inc.'s revenues are expected to be $0.2 million, up 300% from the year-ago quarter.
For the quarter ended March 2026, GoodRx Holdings, Inc. (GDRX - Free Report) reported revenue of $194.01 million, down 4.4% over the same period last year. EPS came in at $0.07, compared to $0.09 in the year-ago quarter.
The reported revenue represents a surprise of +7.73% over the Zacks Consensus Estimate of $180.09 million. With the consensus EPS estimate being $0.07, the EPS surprise was -5.41%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how GoodRx performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Monthly Active Consumers: 5 compared to the 5 average estimate based on three analysts.Subscription plans: 717 versus the two-analyst average estimate of 679.Revenue- Prescription transactions: $113.69 million versus $114.73 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -23.7% change.Revenue- Other: $3.69 million versus the three-analyst average estimate of $3.99 million. The reported number represents a year-over-year change of -15.8%.Revenue- Pharma direct: $52.23 million versus the three-analyst average estimate of $40.07 million. The reported number represents a year-over-year change of +82.3%.Revenue- Subscription: $24.39 million versus $21.68 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +16.1% change.View all Key Company Metrics for GoodRx here>>>
Shares of GoodRx have returned +24.9% over the past month versus the Zacks S&P 500 composite's +10.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Out-of-pocket drug costs are rising for millions of Americans. Coverage gaps are widening. GoodRx is turning both trends into a business.
Pharma Direct, the unit that connects pharmaceutical manufacturers directly to consumers through point-of-sale pricing programs, grew 82% year over year in Q1. The platform now runs more than 125 self-pay programs. GoodRx handled approximately one third of all Wegovy pill transactions in the first two months after launch. Prescription transactions revenue fell 24% year over year.
How GoodRx Became a Drug Access Platform The original GoodRx model was straightforward, allowing consumers to find lower prices on generic drugs at retail pharmacies. That model still runs. But the company has been building a second layer on top of it.
Pharma Direct enables manufacturers to set pricing directly and deliver it to consumers through GoodRx’s extensive retail pharmacy network. When a consumer fills a prescription through one of these programs, the manufacturer’s approved price shows up at the counter. No insurance is required, and no prior authorization is needed. GoodRx handles the infrastructure. The manufacturer owns the program.
“Since the start of the year, we have helped enable access to Ozempic pill, Wegovy HD, Wegovy pill, Zepbound and Zepbound KwikPen,” CEO Wendy Barnes said on the earnings call.
Wegovy pill launched with a cash strategy built around GoodRx from day one. Novo, which manufactures the medication, coordinated supply availability, prescriber education and marketing. GoodRx handled pricing infrastructure and pharmacy access. One third of all Wegovy pill transactions in the first two months post-launch ran through GoodRx.
Advertisement: Scroll to Continue
Beyond GLP-1s, the company announced a collaboration with Viatris covering 17 brand medications and introduced discounts from Pfizer across more than 30 essential medications spanning women’s health, migraine, arthritis and rare disease. Those programs are available through a dedicated Pfizer-branded storefront on GoodRx.
Branded storefronts are becoming a new outreach surface within Pharma Direct. Rather than listing a single drug price, they let consumers explore a manufacturer’s full portfolio of savings in one place.
GoodRx is using artificial intelligence (AI) to shape how affordability is surfaced and discovered within those storefronts, developing new ways for manufacturers to engage patients based on their context and needs.
Growth and Pressures Subscriptions grew 16% year over year. The number of subscription plans returned to year-over-year growth. GoodRx for Weight Loss is the primary driver, expanding to cover all FDA-approved GLP-1 therapies during the quarter. The Wegovy pill performed particularly well since launching at the start of the year.
The subscription model combines clinical care, transparent self-pay pricing and broad pharmacy access. Barnes said the retail network is a key differentiator. Unlike some competitors, GoodRx does not require consumers to use a specific home delivery provider. Instead, the consumer can choose between retail or home delivery. The company is extending the subscription model into the employer channel through GoodRx Employer Direct.
Prescription transactions revenue, the legacy core of the business, fell 24% year over year. Monthly active consumers were flat sequentially at 5.3 million. CFO Chris McGinnis said the company has direct contracts with nine of its top 10 retail pharmacies nationwide. ISP programs are performing consistent with expectations and volume looks relatively stable.
What Else Stood Out TrumpRx is an emerging channel. GoodRx enables pricing for many of the brands available on the platform. Early data shows strong demand concentrated in GLP-1 therapies. Barnes said the volume appears incremental, reaching new consumers who had not previously used GoodRx. Marketing spend was down year over year in Q1. McGinnis said early subscription momentum came largely from organic traffic to the platform. The company expects to increase marketing spend throughout the rest of the year, directing dollars toward condition-specific subscription offerings. The Surescripts partnership announced roughly five months ago has not produced material results. Management said the two companies are still determining how best to deploy the offering. GoodRx is watching macroeconomic trends closely. McGinnis cited rising uninsured rates, Medicaid eligibility changes and ACA subsidy shifts as factors that could affect the business through 2026 and beyond. Top-Line Results and Outlook Q1 2026 revenue was $194 million. Prescription transactions revenue was $113.7 million, down 24% year over year. Pharma Direct revenue was $52.2 million, up 82% year over year. Subscription revenue was $24.4 million, up 16% year over year.
For the full year, GoodRx now expects revenue of $765 million to $785 million and adjusted EBITDA of at least $235 million. Pharma Direct revenue is expected to grow more than 50% year over year. Subscription revenue is expected to build throughout the year as condition-specific programs continue to scale.
GoodRx Holdings, Inc. faces ongoing revenue and margin pressure as its legacy business declines and Pharma Direct grows but with lower profitability. GDRX's Q1 results showed a 4% Y/Y revenue drop and EBITDA margin compression to 18.5%, with management expecting continued legacy erosion through 2026. Valuation sensitivity is highest to margin assumptions; the base DCF value is $2.49/share, near the current price, with scenario analysis skewed toward downside risk.
You turn 65, sign up for Medicare, and a wall of mail arrives pushing standalone Part D drug plans. The default move for decades has been to pick one and forget it. For 2026, that default deserves a fresh look. The Inflation Reduction Act fully kicks in this year, premiums and surcharges shift, and bundled Medicare Advantage plans now compete aggressively for the same enrollees.
Part D still matters. The late enrollment penalty is permanent and often misunderstood. The real question is which drug coverage path fits, especially if you take a few medications today.
The 2026 numbers that frame the decision Part D national base premium of $36.78 per month — This is the benchmark figure CMS uses to calculate late enrollment penalties and IRMAA surcharges. Actual plan premiums vary by carrier and state, but the base premium drives the math behind every surcharge calculation. Maximum Part D deductible of $590 — Plans can charge less, but no standalone drug plan can require you to pay more than this before cost-sharing kicks in. Many low-premium plans hit this cap, so factor it into total-cost comparisons rather than focusing solely on the monthly premium. New annual out-of-pocket cap on prescriptions of $2,000 — This is the headline change from the Inflation Reduction Act. Once your true out-of-pocket drug spending reaches the cap, you pay nothing more for covered medications for the rest of the year, eliminating the old catastrophic coinsurance phase. IRMAA surcharge range for higher-income retirees of $14.50 to $91.00 per month — Retirees with modified adjusted gross income above the thresholds pay this surcharge on top of their plan premium. Because IRMAA is added regardless of which Part D plan you choose, high earners benefit most from selecting the lowest-premium compliant plan. For a retiree paying around $42 a month in premiums for 25 years, the total outlay reaches roughly $12,600, which can exceed what they ever recoup at the pharmacy counter.
Why did the math change this year? The single biggest shift: the $2,000 annual out-of-pocket cap and the elimination of the catastrophic coinsurance phase. Before this rule, a cancer drug or specialty medication could expose a retiree to five-figure annual costs. Now the worst-case pharmacy bill is capped. Premiums now fund routine cost-sharing on prescriptions you actually fill, with catastrophic risk already capped.
For a retiree on no medications, the expected value of a richer plan drops sharply. For someone on three or four maintenance drugs, the cap is still useful, but the premium gap between the cheapest plan and a mid-tier plan rarely pays off.
The trap on the other side is the late enrollment penalty. Skip Part D for five years and the Social Security Administration adds about $22 a month to your premium for life. That is roughly $264 a year, every year, forever. The penalty math alone is why a placeholder plan beats no plan.
Three reasons to reconsider a standalone plan The cheapest compliant plan often wins. If you take few or no drugs, Part D’s role in 2026 is mainly to avoid the lifetime penalty and give you access to the $2,000 cap if your health changes. Paying for a richer formulary you don’t use is a drag. The lowest-premium plan in your state, paired with GoodRx (NASDAQ: GDRX | GDRX Price Prediction) or Costco (NASDAQ: COST) cash pricing for cheap generics, frequently beats a mid-tier plan on total spend. A Medicare Advantage drug plan (MA-PD) may already include it. If you are weighing Original Medicare plus Medigap plus standalone Part D against an MA-PD bundle, the bundle combines drug coverage into a single premium. The tradeoff is network restrictions and prior authorization. For healthy retirees who value a single bill and lower upfront cost, MA-PD removes the standalone Part D decision entirely. For those who travel often or want any-doctor access, Original Medicare plus standalone Part D still wins. IRMAA surcharges punish high earners twice. A retiree in the top income bands pays the Part B surcharge plus a Part D IRMAA of up to $91 a month, pushing annual Part D cost toward $1,533 in premiums alone before a single prescription is filled. If your modified AGI puts you in IRMAA territory, the cheapest base plan limits the surcharge damage, since IRMAA is added on top regardless of which plan you choose. What to do during open enrollment Evaluate your actual medication list and your projected income two years out, since IRMAA looks back. If you have creditable drug coverage through a former employer or a spouse’s active plan, document it. That coverage defers the penalty clock, and losing it later triggers a special enrollment window without lifetime surcharges.
The common, costly mistake is autopilot. Plans change formularies and premiums every year. Re-shop annually on Medicare.gov’s plan finder using your current drug list. Five minutes of effort routinely saves several hundred dollars, and it is the only way to ensure the cap, the premium, and your prescriptions still line up.
SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for prescription savings in the U.S., today launched GoodRx Companion, a new $14.99-per-month subscription that brings together free and low-cost generic medications, affordable online care visits, and savings on additional healthcare services in one simple program. Built for a healthcare environment where consumers are increasingly shouldering more out-of-pocket costs, even when they have insurance, Companion tu.
GoodRx Launches GoodRx Companion, a New Subscription Designed to Lower Everyday Healthcare Costs GoodRx (Nasdaq: GDRX), the leading platform for prescription savings in the U.S., today launched GoodRx Companion, a new $14.99-per-month subscription that brings together free and low-cost generic medications, affordable online care visits, and savings on additional healthcare services in one simple program. Built for a healthcare environment where consumers are increasingly shouldering more out-of-pocket costs, even when they have insurance, Companion turns the pricing capabilities, retail pharmacy relationships, and consumer experience GoodRx has built over more than a decade into a membership designed to make everyday care more affordable and predictable.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260527868807/en/
“GoodRx Companion is an important step in our evolution toward building a broader subscription model built for the way consumers are navigating healthcare today,” said Wendy Barnes, President and CEO of GoodRx. “As coverage becomes more complex and out-of-pocket costs continue to rise, people are looking for trusted solutions that give them greater control and clearer value. Companion meets that demand while advancing our strategy to build deeper, more recurring consumer relationships across a growing portfolio of subscription offerings. This is where we believe the market is headed, and where we believe GoodRx is uniquely positioned to lead.”
One Membership. More Ways to Save.
Companion gives consumers a more comprehensive way to save on routine healthcare, combining lower discounted cash prices on prescriptions with more affordable access to the care and services they use throughout the year. Companion is particularly beneficial to patients managing chronic conditions, those who are taking multiple medications, or those with health insurance coverage limitations.
Benefits include:
Prescription savings: More than 200 common generic medications for free, with hundreds more for less than $10, available at nearly every pharmacy nationwide Online care: $19 telehealth visits on GoodRx Care for common needs such as UTIs, skin care, flu, and other routine conditions Dental care: Savings on cleanings, exams, X-rays, crowns, and other dental services Vision care: Savings on eye exams, glasses, contact lenses, and laser eye surgery Lab and imaging services: Significant savings on common lab and imaging services such as MRIs, CT scans, ultrasounds, comprehensive wellness labs, and hormone panels A Broader Subscription Model for a Changing Healthcare Market
The launch of Companion advances GoodRx’s subscription strategy by adding a broader membership offering alongside its condition-focused offerings for weight loss, erectile dysfunction, and hair loss. It creates another recurring revenue stream, gives GoodRx a more continuous way to engage consumers beyond individual prescription transactions, and strengthens the company’s move toward a more diversified membership model with favorable pharmacy economics.
To learn more, visit: www.goodrx.com/companion
About GoodRx
GoodRx is the leading platform for medication savings in the U.S., used by nearly 25 million consumers and over one million healthcare professionals annually. Uniquely situated at the center of the healthcare ecosystem, GoodRx connects consumers, healthcare professionals, payers, PBMs, pharma manufacturers, and retail pharmacies to make saving on medications easier. By reducing friction and inefficiencies, GoodRx helps consumers save time and money when filling prescriptions so they can get the care they deserve. Since 2011, GoodRx has helped Americans save over $100 billion on the cost of their medications.
GoodRx periodically posts information that may be important to investors on its investor relations website at https://investors.goodrx.com. We intend to use our website as a means of disclosing material nonpublic information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors and potential investors are encouraged to consult GoodRx’s website regularly for important information, in addition to following GoodRx’s press releases, filings with the Securities and Exchange Commission (the “SEC”) and public conference calls and webcasts. The information contained on, or that may be accessed through, GoodRx’s website is not incorporated by reference into, and is not a part of, this press release.
GoodRx Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding anticipated consumer savings, convenience and accessibility; the expected benefits, pricing and value of GoodRx Companion and related pricing; and our plans, expectations and objectives. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, risks relating to our ability to achieve broad market education and change consumer purchasing habits; changes in medication pricing and pricing structures; our reliance on a limited number of industry participants; and the important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, and our other filings with the SEC. Any such forward-looking statements are based on current expectations, projections and estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260527868807/en/
PORTSMOUTH, N.H.--(BUSINESS WIRE)--Albany International Corp. (NYSE:AIN) today announced that it will participate in the upcoming J.P. Morgan conference in Washington, D.C. During the conference, Will Station, Executive Vice President and Chief Financial Officer of Albany International Corp., will participate in a fireside chat on Tuesday, March 17, 2026, at 11:30 AM. An audio webcast of the event can be accessed via the Albany International website at www.albint.com or by clicking here. A repl.
Albany International (NYSE: AIN) CFO Willard Station said the company delivered a strong fourth quarter in its Aerospace Engineered Composites (AEC) segment, but cautioned that the pace of growth in the period included items that are not expected to recur. Speaking at a JPMorgan event hosted by analyst Chigusa Katoku, Station also provided updates on Albany's
PORTSMOUTH, N.H.--(BUSINESS WIRE)--Albany Engineered Composites® (AEC), a segment of Albany International Corp. (NYSE: AIN), announced today it has been named one of America's Safest Companies by EHS Today, recognizing world-class environmental, health and safety (EHS) performance across U.S. industry. “Safety at AEC is not a program — it's a mindset embedded in how we design processes, train our teams and operate every day,” said Ashley Dobbs, vice president, integrated operations and transfor.
Albany International Corporation (NYSE:AIN – Get Free Report) has received an average recommendation of “Reduce” from the six research firms that are covering the company, Marketbeat reports. Two research analysts have rated the stock with a sell recommendation and four have issued a hold recommendation on the company. The average twelve-month price target among brokers that have covered the stock in the last year is $61.50.
A number of research firms recently issued reports on AIN. Zacks Research raised shares of Albany International from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 3rd. Truist Financial set a $55.00 target price on shares of Albany International in a research report on Friday, January 9th. JPMorgan Chase & Co. increased their target price on shares of Albany International from $45.00 to $47.00 and gave the stock a “neutral” rating in a research report on Friday, January 16th. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Albany International in a research report on Friday, March 27th.
Read Our Latest Report on Albany International
Institutional Trading of Albany International A number of institutional investors and hedge funds have recently bought and sold shares of the business. T. Rowe Price Investment Management Inc. acquired a new stake in Albany International during the 4th quarter worth approximately $10,323,000. Invesco Ltd. grew its position in Albany International by 5.4% in the fourth quarter. Invesco Ltd. now owns 113,792 shares of the textile maker’s stock valued at $5,769,000 after acquiring an additional 5,802 shares in the last quarter. XTX Topco Ltd acquired a new stake in Albany International in the fourth quarter valued at approximately $2,887,000. Voloridge Investment Management LLC grew its position in Albany International by 40.9% in the fourth quarter. Voloridge Investment Management LLC now owns 229,477 shares of the textile maker’s stock valued at $11,634,000 after acquiring an additional 66,569 shares in the last quarter. Finally, Quadrature Capital Ltd acquired a new stake in Albany International in the fourth quarter valued at approximately $499,000. Institutional investors and hedge funds own 97.37% of the company’s stock.
Albany International Trading Up 1.3% NYSE AIN opened at $52.92 on Friday. Albany International has a 12 month low of $41.15 and a 12 month high of $73.00. The company has a 50-day moving average of $55.75 and a 200-day moving average of $53.85. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.10 and a quick ratio of 1.83. The company has a market cap of $1.50 billion, a P/E ratio of -26.20, a P/E/G ratio of 2.02 and a beta of 1.18.
Albany International (NYSE:AIN – Get Free Report) last posted its quarterly earnings data on Tuesday, February 24th. The textile maker reported $0.65 EPS for the quarter, beating analysts’ consensus estimates of $0.64 by $0.01. The company had revenue of $321.21 million during the quarter, compared to the consensus estimate of $292.32 million. Albany International had a negative net margin of 4.85% and a positive return on equity of 9.64%. The company’s quarterly revenue was up 12.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.58 EPS. Albany International has set its Q1 2026 guidance at 0.500-0.600 EPS. As a group, equities analysts predict that Albany International will post 3.23 earnings per share for the current year.
Albany International Announces Dividend The firm also recently announced a quarterly dividend, which will be paid on Tuesday, April 7th. Investors of record on Friday, March 20th will be given a dividend of $0.28 per share. This represents a $1.12 dividend on an annualized basis and a yield of 2.1%. The ex-dividend date of this dividend is Friday, March 20th. Albany International’s dividend payout ratio is -55.45%.
About Albany International (Get Free Report)
Albany International Corp. is a global advanced materials company specializing in engineered textiles and composites. Its business is organized into two primary segments: Process Media and Engineered Composites. The Process Media segment designs, manufactures and services press, forming and drying fabrics used in the production of paper and packaging materials, helping paper manufacturers improve efficiency, quality and sustainability. The Engineered Composites segment produces lightweight composite structures and components for aerospace and industrial applications, serving commercial and military aircraft programs as well as industrial markets that require high-performance, durable materials.
In the Process Media segment, Albany’s products include forming fabrics, press felts and dryer fabrics engineered to withstand extreme moisture and temperature conditions.
Further Reading Five stocks we like better than Albany International
Receive News & Ratings for Albany International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albany International and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEWix.com Sees Unusually Large Options Volume (NASDAQ:WIX)
NEXT HEADLINE »Traders Purchase Large Volume of STMicroelectronics Call Options (NYSE:STM)
SG Americas Securities LLC boosted its position in Albany International Corporation (NYSE:AIN – Free Report) by 287.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 31,692 shares of the textile maker’s stock after purchasing an additional 23,502 shares during the quarter. SG Americas Securities LLC owned approximately 0.11% of Albany International worth $1,607,000 at the end of the most recent quarter.
A number of other hedge funds have also recently modified their holdings of the business. Smartleaf Asset Management LLC grew its stake in shares of Albany International by 32.4% in the 2nd quarter. Smartleaf Asset Management LLC now owns 711 shares of the textile maker’s stock worth $49,000 after buying an additional 174 shares during the last quarter. California State Teachers Retirement System boosted its holdings in Albany International by 0.6% in the second quarter. California State Teachers Retirement System now owns 28,783 shares of the textile maker’s stock worth $2,019,000 after acquiring an additional 179 shares in the last quarter. Blue Trust Inc. boosted its holdings in Albany International by 6.1% in the third quarter. Blue Trust Inc. now owns 3,433 shares of the textile maker’s stock worth $183,000 after acquiring an additional 196 shares in the last quarter. Dakota Wealth Management grew its stake in shares of Albany International by 1.8% in the third quarter. Dakota Wealth Management now owns 13,878 shares of the textile maker’s stock worth $740,000 after acquiring an additional 245 shares during the last quarter. Finally, Osaic Holdings Inc. increased its holdings in shares of Albany International by 42.3% during the second quarter. Osaic Holdings Inc. now owns 908 shares of the textile maker’s stock valued at $64,000 after acquiring an additional 270 shares in the last quarter. Institutional investors own 97.37% of the company’s stock.
Albany International Trading Up 1.3% NYSE:AIN opened at $52.92 on Tuesday. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.10 and a quick ratio of 1.83. The firm has a market capitalization of $1.50 billion, a price-to-earnings ratio of -26.20, a price-to-earnings-growth ratio of 2.02 and a beta of 1.18. Albany International Corporation has a one year low of $41.15 and a one year high of $73.00. The business has a fifty day moving average price of $55.75 and a 200-day moving average price of $53.85.
Albany International (NYSE:AIN – Get Free Report) last posted its quarterly earnings data on Tuesday, February 24th. The textile maker reported $0.65 earnings per share for the quarter, beating analysts’ consensus estimates of $0.64 by $0.01. The firm had revenue of $321.21 million for the quarter, compared to analysts’ expectations of $292.32 million. Albany International had a positive return on equity of 9.64% and a negative net margin of 4.85%.The business’s quarterly revenue was up 12.0% on a year-over-year basis. During the same period in the previous year, the firm earned $0.58 EPS. Albany International has set its Q1 2026 guidance at 0.500-0.600 EPS. Sell-side analysts forecast that Albany International Corporation will post 3.23 EPS for the current year.
Albany International Announces Dividend The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 7th. Shareholders of record on Friday, March 20th will be paid a $0.28 dividend. The ex-dividend date of this dividend is Friday, March 20th. This represents a $1.12 dividend on an annualized basis and a yield of 2.1%. Albany International’s payout ratio is presently -55.45%.
Analyst Upgrades and Downgrades Several brokerages recently weighed in on AIN. Weiss Ratings reissued a “sell (d)” rating on shares of Albany International in a research report on Friday, March 27th. Truist Financial set a $55.00 price objective on Albany International in a research report on Friday, January 9th. JPMorgan Chase & Co. lifted their target price on Albany International from $45.00 to $47.00 and gave the stock a “neutral” rating in a report on Friday, January 16th. Finally, Zacks Research upgraded Albany International from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 3rd. Four equities research analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Reduce” and a consensus price target of $61.50.
View Our Latest Research Report on AIN
Albany International Profile (Free Report)
Albany International Corp. is a global advanced materials company specializing in engineered textiles and composites. Its business is organized into two primary segments: Process Media and Engineered Composites. The Process Media segment designs, manufactures and services press, forming and drying fabrics used in the production of paper and packaging materials, helping paper manufacturers improve efficiency, quality and sustainability. The Engineered Composites segment produces lightweight composite structures and components for aerospace and industrial applications, serving commercial and military aircraft programs as well as industrial markets that require high-performance, durable materials.
In the Process Media segment, Albany’s products include forming fabrics, press felts and dryer fabrics engineered to withstand extreme moisture and temperature conditions.
See Also Five stocks we like better than Albany International
Receive News & Ratings for Albany International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albany International and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEJPMorgan Chase & Co. Trims Stock Position in Alliance Resource Partners, L.P. $ARLP
NEXT HEADLINE »Quantum Computing Inc. $QUBT Shares Sold by SG Americas Securities LLC
Deprince Race & Zollo Inc. bought a new position in shares of Albany International Corporation (NYSE:AIN – Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 365,025 shares of the textile maker’s stock, valued at approximately $18,507,000. Deprince Race & Zollo Inc. owned about 1.27% of Albany International as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds and other institutional investors have also recently modified their holdings of AIN. EverSource Wealth Advisors LLC boosted its position in shares of Albany International by 227.3% during the second quarter. EverSource Wealth Advisors LLC now owns 540 shares of the textile maker’s stock worth $38,000 after acquiring an additional 375 shares during the last quarter. Smartleaf Asset Management LLC boosted its position in shares of Albany International by 32.4% during the second quarter. Smartleaf Asset Management LLC now owns 711 shares of the textile maker’s stock worth $49,000 after acquiring an additional 174 shares during the last quarter. Osaic Holdings Inc. boosted its position in shares of Albany International by 42.3% during the second quarter. Osaic Holdings Inc. now owns 908 shares of the textile maker’s stock worth $64,000 after acquiring an additional 270 shares during the last quarter. Aster Capital Management DIFC Ltd bought a new position in shares of Albany International during the third quarter worth $66,000. Finally, Lazard Asset Management LLC bought a new position in shares of Albany International during the second quarter worth $77,000. Institutional investors own 97.37% of the company’s stock.
Wall Street Analysts Forecast Growth A number of equities analysts recently weighed in on AIN shares. Zacks Research upgraded shares of Albany International from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 3rd. Truist Financial set a $55.00 target price on shares of Albany International in a research report on Friday, January 9th. JPMorgan Chase & Co. upped their target price on shares of Albany International from $45.00 to $47.00 and gave the stock a “neutral” rating in a research report on Friday, January 16th. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Albany International in a research report on Friday, March 27th. Four equities research analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Reduce” and a consensus price target of $61.50.
Get Our Latest Stock Analysis on Albany International
Albany International Trading Up 1.0% AIN stock opened at $57.76 on Tuesday. The company has a quick ratio of 1.83, a current ratio of 2.10 and a debt-to-equity ratio of 0.62. Albany International Corporation has a twelve month low of $41.15 and a twelve month high of $73.00. The stock has a market capitalization of $1.63 billion, a price-to-earnings ratio of -28.59, a price-to-earnings-growth ratio of 2.34 and a beta of 1.18. The firm’s fifty day simple moving average is $55.76 and its two-hundred day simple moving average is $53.88.
Albany International (NYSE:AIN – Get Free Report) last posted its quarterly earnings data on Tuesday, February 24th. The textile maker reported $0.65 earnings per share for the quarter, beating analysts’ consensus estimates of $0.64 by $0.01. Albany International had a negative net margin of 4.85% and a positive return on equity of 9.64%. The business had revenue of $321.21 million for the quarter, compared to analysts’ expectations of $292.32 million. During the same quarter in the previous year, the business posted $0.58 earnings per share. The business’s revenue was up 12.0% compared to the same quarter last year. Albany International has set its Q1 2026 guidance at 0.500-0.600 EPS. As a group, analysts anticipate that Albany International Corporation will post 3.23 earnings per share for the current year.
Albany International Dividend Announcement The business also recently announced a quarterly dividend, which was paid on Tuesday, April 7th. Stockholders of record on Friday, March 20th were paid a dividend of $0.28 per share. This represents a $1.12 dividend on an annualized basis and a dividend yield of 1.9%. The ex-dividend date of this dividend was Friday, March 20th. Albany International’s payout ratio is currently -55.45%.
About Albany International (Free Report)
Albany International Corp. is a global advanced materials company specializing in engineered textiles and composites. Its business is organized into two primary segments: Process Media and Engineered Composites. The Process Media segment designs, manufactures and services press, forming and drying fabrics used in the production of paper and packaging materials, helping paper manufacturers improve efficiency, quality and sustainability. The Engineered Composites segment produces lightweight composite structures and components for aerospace and industrial applications, serving commercial and military aircraft programs as well as industrial markets that require high-performance, durable materials.
In the Process Media segment, Albany’s products include forming fabrics, press felts and dryer fabrics engineered to withstand extreme moisture and temperature conditions.
Featured Articles Five stocks we like better than Albany International Want to see what other hedge funds are holding AIN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Albany International Corporation (NYSE:AIN – Free Report).
Receive News & Ratings for Albany International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albany International and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEAssetmark Inc. Raises Stock Position in Procter & Gamble Company (The) $PG
NEXT HEADLINE »Pool Corporation $POOL Shares Acquired by Deprince Race & Zollo Inc.
PORTSMOUTH, N.H.--(BUSINESS WIRE)--Albany International Corp. (NYSE:AIN) announced today that it will release first-quarter 2026 results on April 30, 2026, before market open. The Company will host a webcast to discuss the results at 8:30 a.m. Eastern Time on Thursday, April 30, 2026. Interested parties are encouraged to listen to the live webcast via the Company's Investor Relations website at investors.albint.com or by registering via the link here. The event can also be accessed by dialing +.
Albany International remains rated 'hold' due to mixed financial performance and unimpressive valuation metrics. Recent results show top-line growth but continued bottom-line weakness, with the Machine Clothing segment hit by declining demand and China exposure. AIN's Engineered Composites segment shows relative strength, supported by acquisitions and defense programs, but overall profitability remains pressured.
PORTSMOUTH, N.H.--(BUSINESS WIRE)--Albany Engineered Composites (AEC), a segment of Albany International Corp. (NYSE: AIN), has received a long-term contract from Pratt & Whitney, an RTX business, to produce composite structural engine components for the commercial aviation Pratt & Whitney GTF™ engine. “We are honored to be selected by Pratt & Whitney for this critical composite engine content. This award reflects AEC's ability to deliver high-volume, high-precision composite struct.
PORTSMOUTH, N.H.--(BUSINESS WIRE)--Albany International Corp. (NYSE:AIN) today reported operating results for its first quarter of 2026, which ended March 31, 2026. Gunnar Kleveland, Albany International's President and Chief Executive Officer said, “Over the past year, we have taken steps to de-risk the business by addressing underperforming areas and sharpening our focus on profitable growth. This has driven a strong start to 2026, with results at the top end of our expectations.” Kleveland c.
Albany International (AIN - Free Report) came out with quarterly earnings of $0.6 per share, beating the Zacks Consensus Estimate of $0.55 per share. This compares to earnings of $0.73 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of +9.09%. A quarter ago, it was expected that this textile and composite maker would post earnings of $0.64 per share when it actually produced earnings of $0.65, delivering a surprise of +1.56%.
Over the last four quarters, the company has surpassed consensus EPS estimates three times.
Albany International, which belongs to the Zacks Textile - Products industry, posted revenues of $311.33 million for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 10.30%. This compares to year-ago revenues of $288.77 million. The company has topped consensus revenue estimates three times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Albany International shares have added about 14.4% since the beginning of the year versus the S&P 500's gain of 4.2%.
What's Next for Albany International?While Albany International has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Albany International was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.75 on $314.3 million in revenues for the coming quarter and $2.91 on $1.2 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Textile - Products is currently in the top 39% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
One other stock from the same industry, Unifi (UFI - Free Report) , is yet to report results for the quarter ended March 2026. The results are expected to be released on May 5.
This polyester and nylon yarn maker is expected to post quarterly loss of $0.22 per share in its upcoming report, which represents a year-over-year change of +71.1%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Unifi's revenues are expected to be $130.72 million, down 10.8% from the year-ago quarter.
PORTSMOUTH, N.H.--(BUSINESS WIRE)--The Board of Directors of Albany International Corp. (NYSE: AIN) today declared a quarterly dividend of $0.28 per share on the Company's Class A Common Stock. The dividend is payable July 7, 2026, to shareholders of record on June 5, 2026. About Albany International Corp. Albany is a leading materials science developer and manufacturer of engineered components, using advanced materials processing and automation capabilities, with two core businesses: Machine C.
The Board of Directors of Albany International Corp. (NYSE: AIN) today declared a quarterly dividend of $0.28 per share on the Company’s Class A Common Stock.
The dividend is payable July 7, 2026, to shareholders of record on June 5, 2026.
About Albany International Corp.
Albany is a leading materials science developer and manufacturer of engineered components, using advanced materials processing and automation capabilities, with two core businesses:
Machine Clothing is the world’s leading producer of custom-designed consumable belts, essential for the manufacture of paper, paperboard, tissue, and towel, as well as pulp, non-wovens, and a variety of other industrial applications. Albany Engineered Composites is a growing designer and manufacturer of advanced materials-based engineered components for demanding aerospace applications, supporting both commercial and military platforms. Albany International is headquartered in Portsmouth, New Hampshire, operates 25 facilities in 12 countries, employs approximately 5,700 people worldwide, and is listed on the New York Stock Exchange (Symbol AIN). Additional information about the Company and its products and services can be found at www.albint.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260518958672/en/
ROCHESTER, N.H.--(BUSINESS WIRE)--Albany Engineered Composites (AEC), a segment of Albany International Corp. (NYSE: AIN), today announced it will exhibit at the Farnborough International Airshow 2026 from July 20–24, 2026, in Hall 3, Booth 3330. At the world's premier annual aerospace industry event, AEC will highlight its state-of-the-art composite solutions and vertically integrated manufacturing capabilities supporting current and next-generation commercial aerospace, defense, missile, spac.
PORTSMOUTH, N.H.--(BUSINESS WIRE)--Albany International Corp. (NYSE:AIN) today announced that it will participate in the upcoming Wells Fargo 16th Industrials & Materials Conference in Chicago and the 2026 Truist Industrial & Services Conference in New York. At the Wells Fargo Conference, Gunnar Kleveland, Chief Executive Officer and Will Station, Chief Financial Officer, will participate in a fireside chat on Wednesday, June 10, 2026, at 10:15 AM CT. An audio webcast of the Wells Fargo.
On June 04, 2026, Albany International Corp AIN shares rose 7.7% today, closing at $68.69. This follows a strong price performance over the last month, where shares have increased by 20.1%. The stock has traded between $41.15 and $73.00 over the past year, highlighting significant volatility.
GF Value™ verdict: Current price is $68.69, compared to a fair value of $84.09, indicating the stock is 18.3% undervalued. GF Score™ of 70/100 indicates the company is rated as Above Average based on key financial metrics. Notable signal: Momentum rank is 7/10, suggesting positive short-term price trends. Is AIN Overvalued or Undervalued? Albany International Corp's current price of $68.69 is significantly below the GF Value™ of $84.09, suggesting that the stock is undervalued by 18.3%. This margin of safety presents a potential opportunity for investors looking for stocks with a favorable risk-reward profile. The GF Valuation label characterizes the stock as Modestly Undervalued, which may attract those seeking investments with intrinsic value that is not fully recognized by the market. GF Value™ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates.
While the undervaluation indicates a potential buying opportunity, investors should remain cautious. Factors such as financial strength and growth rank (2/10) may suggest underlying challenges that could impact future performance. Therefore, while the current pricing seems favorable in terms of GF Value™, it is essential to consider the broader financial context before making any decisions.
How Does AIN's Valuation Compare to Its History? Metric Current Historical P/E (TTM) 26.5x 25.6x The current forward P/E of 26.5x is slightly above the 5-year median P/E of 25.6x. This suggests that the stock is trading at a premium compared to its historical valuation. The P/E analysis aligns with the GF Value™ verdict, which indicates that the stock is undervalued. However, the higher current P/E ratio may warrant further scrutiny regarding the sustainability of its valuation moving forward.
What Does AIN's GF Score™ Tell Us? Metric Rating GF Score™ 70/100 Financial Strength 4/10 Profitability 7/10 Growth 2/10 Valuation 8/10 Momentum 7/10 The GF Score™ of 70/100 reflects a solid performance in profitability (7/10) and valuation (8/10), indicating that while the company generates profits effectively, there may be room for improvement in growth (2/10) and financial strength (4/10). The relatively high momentum rank (7/10) suggests that the stock has been performing well in the short term, potentially appealing to trend-focused investors.
What Are Insiders Doing with AIN Stock? In the last three months, there have been no insider transactions reported for Albany International Corp. This absence of insider buying or selling may suggest that company executives believe the stock is fairly priced, or they may be anticipating future movements without taking immediate action. Investors often look to insider transactions as a signal of company health, so the lack of activity could be a neutral indicator at this time.
What This Means for Investors Based on the GF Value™ assessment, Albany International Corp AIN is currently undervalued, presenting a potential buying opportunity. However, investors should consider the company's financial strength and growth potential before making any decisions.
For the complete analysis, visit the Albany International Corp AIN stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.
Frequently Asked Questions What is AIN's GF Score™?
AIN's GF Score™ is 70/100, indicating that the stock is rated as Above Average based on key financial metrics.
Is AIN overvalued or undervalued?
AIN is currently undervalued, with a GF Value™ of $84.09 compared to its current price of $68.69.
What is AIN's P/E ratio?
AIN's forward P/E is 26.5x, which is slightly above its 5-year median P/E of 25.6x, suggesting it is trading at a premium compared to its historical valuation.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
PORTSMOUTH, N.H.--(BUSINESS WIRE)--Albany International Corp. (NYSE:AIN) announced today the publication of its annual Sustainability Report, highlighting the company's achievements and commitments to sustainability and innovation in 2025. “Our foundation is supporting our customers with continued innovation and building a resilient organization, and our sustainability strategy is critical to meet those objectives. We are proud to showcase our progress over the last year in our annual sustainab.
PORTSMOUTH, N.H.--(BUSINESS WIRE)--Albany International Corp. (NYSE:AIN) today reports continued progress in the ongoing project with Cyclezyme AB, a leader in advanced enzyme-based plastic recycling, based in Sweden. The project exemplifies leading edge innovation in materials science, focusing on the development of enzyme-based recycling of industrial textiles primarily consisting of polyester and polyamide, where there is currently a significant lack of effective solutions for circular mater.
Issued on behalf of Integrated Cyber Solutions Inc. dba Integrated Quantum Technologies (CSE: ICS) (OTCQB: IGCRF) (FSE: Y4G)
As enterprises rush to deploy autonomous AI agents, a new security problem is emerging that the old cybersecurity playbook wasn't built for — and a small Vancouver-based company just put a flag in the ground with a framework called MASQ.
USA News Group News Commentary
, /PRNewswire/ -- Every few years, enterprise technology produces a category that didn't exist the year before. In 2026, that category is AI agent security. Autonomous AI agents — software that can reason, make decisions, and take actions across a company's systems without a human pressing every button — are moving from pilot projects into production at remarkable speed. And with them comes a problem the traditional security stack was never designed to solve: how do you control what an AI agent is allowed to see, what it's allowed to do, and how its internal reasoning is protected while it's doing it?
Integrated Cyber Solutions Inc., doing business as Integrated Quantum Technologies (CSE: ICS) (OTCQB: IGCRF) (FSE: Y4G), just announced its answer. The company has initiated the patent process for MASQ™ — short for Machine Action Security Quotient — a governance and security framework built specifically for AI agents and autonomous AI systems.
What MASQ is actually trying to solve
The pitch is straightforward once you see the problem it targets. Today's AI agents don't just answer questions; they connect to APIs, call external tools, query enterprise databases, and increasingly talk to other agents through emerging plumbing like MCP (Model Context Protocol) servers. Each of those connection points is a place where an agent could access something it shouldn't, take an action nobody authorized, or leak sensitive information held in its working memory.
MASQ is designed to sit across those control points and govern four things: what permissions and actions an agent is authorized to perform; what enterprise systems and data it can reach; how it interacts with APIs, external tools, and MCP servers; and — the most distinctive piece — how the sensitive information inside an agent's context window, internal attention states, and reasoning environment is protected during machine-to-machine interaction. That last element is the part most traditional cybersecurity architectures simply don't address, because they were built to protect networks and endpoints, not the live reasoning state of an autonomous machine.
"AI agents are becoming increasingly autonomous and interconnected, and organizations will require governance systems capable of controlling not only what agents can access and execute, but also how sensitive contextual reasoning data is protected during machine-to-machine interaction," said Jeremy J. Samuelson, EVP, Artificial Intelligence & Innovation at Integrated Quantum, who joined the company in January 2026 after serving as Principal Data and AI Scientist for Digital Identity Engineering at Equifax and is credited as the inventor of the company's VEIL technology. "This patent initiative reflects our continued focus on building foundational infrastructure for secure enterprise AI deployment."
A piece of a bigger platform
MASQ isn't a standalone bet. The company intends it to become a core component of its broader AIQu™ platform — a security-first, privacy-preserving, and what the company describes as quantum-resilient AI infrastructure layer. AIQu's first commercial product, VEIL™ (Vector-Encoded Information Layer), is the company's patent-pending technology aimed at protecting sensitive data across the enterprise AI and machine-learning pipeline by reducing the need to expose raw data in the first place. The company also markets a SecureGuard360™ cybersecurity platform and a managed-services offering.
It's worth being precise about where MASQ stands today, because the language matters. The company has initiated the patent process and engaged intellectual property counsel — this is the beginning of a filing effort, not a granted patent or even, on its face, a completed application. MASQ is described as "being developed." For investors, that distinction is the difference between a roadmap and a shipping product, and it should be read as the former. The company's earlier AIQu provisional patent filing (30 claims, filed in January 2026) is a separate matter from this MASQ initiative.
Why the timing is the story
The reason a framework like MASQ is getting attention has less to do with this one microcap and more to do with how fast the surrounding market is moving. The numbers from the established players tell the story.
In January 2026, Gartner projected that AI-cybersecurity spending — covering both securing AI and using AI to defend — would grow at a roughly 74% compound annual rate from 2024 through 2029, more than double the growth rate of AI spending overall. That is the kind of forecast that pulls every serious security vendor into the space, and they have arrived. The agentic-AI-security category now has real product from the largest names in cybersecurity, which is both validation of the thesis and a sharp reminder of how much competition a microcap faces.
How IQT sits among the companies defining this space
To understand the market MASQ is entering, it helps to look at what the established public companies are already shipping. These are not peers of IQT in scale — they are giants, and the contrast is the point: IQT is a microcap staking an early claim in a category these companies are pouring resources into.
CrowdStrike (NASDAQ: CRWD) has moved aggressively into agentic security, launching its Charlotte AI AgentWorks ecosystem and tools explicitly designed to secure AI agents and govern "shadow AI" across endpoints, SaaS, and cloud. CrowdStrike's scale — and the breadth of its launch partners — illustrates how central agent governance has become to the enterprise security roadmap.
Palo Alto Networks (NASDAQ: PANW) made the category's biggest statement by completing its roughly US$25 billion acquisition of identity-security leader CyberArk in February 2026, explicitly to secure "human, machine, and agentic identity." That deal — one of the largest in cybersecurity history — is the clearest possible signal that controlling what autonomous agents can access and do is now seen as foundational infrastructure, not a niche feature.
Okta (NASDAQ: OKTA) has reframed identity itself around the agentic era with "Okta for AI Agents," a platform (generally available April 30, 2026) built to discover both sanctioned and unsanctioned AI agents, treat them as governed identities, and apply lifecycle controls. Okta's framing — that identity becomes a runtime system continuously evaluating what an agent does — maps closely to the problem MASQ describes.
SentinelOne (NYSE: S) introduced Prompt AI Agent Security, a real-time discovery and governance control plane for AI agents and agentic workflows that explicitly enforces policy across MCP servers operating in a customer's environment — the same machine-to-machine connection layer MASQ targets. SentinelOne's product is perhaps the closest functional analog to what IQT describes, deployed at enterprise scale.
The honest takeaway from that lineup cuts both ways. On one hand, the presence of CrowdStrike, Palo Alto, Okta, and SentinelOne validates that AI agent governance is a real and rapidly growing market. On the other, it means a pre-revenue microcap with a framework still in development is entering a field crowded with extraordinarily well-resourced incumbents. Both things are true at once, and investors should hold them together.
The market-awareness piece
Alongside the MASQ news, IQT announced two business-development moves. It appointed Euroswiss Capital Partners Inc., a Switzerland-based capital-markets advisory firm, as a strategic marketing and financial-advisory partner under a 12-month, non-exclusive consulting agreement (fixed fee of $100,000) to raise the company's profile across central Europe; an affiliate of Euroswiss holds 200,000 common shares, and the agreement was negotiated at arm's length. Separately, the company entered an investor-awareness agreement to support North American financial-news distribution. These are visibility initiatives — the kind small-cap issuers commonly use to broaden their investor reach — and they should be understood as marketing arrangements rather than indicators of commercial traction for MASQ itself.
The bottom line
MASQ is an early-stage idea aimed squarely at a real and fast-growing problem. The thesis behind it — that autonomous AI agents need a governance layer purpose-built for what they can access, what they can do, and how their reasoning is protected — is being independently validated by the largest companies in cybersecurity, which are spending billions to address exactly that. That's the bull case.
The bear case is equally plain: IQT is a microcap that has initiated a patent process on a framework still in development, in a category where it competes against some of the best-capitalized security companies on the planet. Whether MASQ becomes a defensible product, a licensed piece of intellectual property, or simply an early marker of ambition is a question that only execution — and time — will answer. What the company has done is plant a flag in one of the most consequential enterprise-technology shifts of the decade. What it builds on that claim is the part still to be written.
For full company detail and ongoing updates, visit IQT's USA News Group landing page: https://usanewsgroup.com/ics-landing/
Integrated Cyber Solutions Inc. dba Integrated Quantum Technologies, "Integrated Quantum Technologies Debuts MASQ™, an AI Agent Governance and Security Architecture, Initiates Patent Process, and Announces Strategic Market Awareness Initiatives," Newsfile Corp., May 28, 2026.Integrated Quantum Technologies, "Files Provisional Patent for Post-Quantum AI Infrastructure Platform, AIQu" (30 claims; VEIL™), January 13, 2026; EVP AI appointment (Jeremy Samuelson), January 2026.CrowdStrike Holdings, "CrowdStrike Launches the Charlotte AI AgentWorks Ecosystem," March 25, 2026; "Secure AI Agents and Govern Shadow AI," March 2026.Palo Alto Networks, "Palo Alto Networks Completes Acquisition of CyberArk to Secure the AI Era," February 11, 2026.Okta, "Okta announces new blueprint for the secure agentic enterprise" / "Okta for AI Agents" (GA April 30, 2026), March 2026.SentinelOne, "SentinelOne Unveils New AI Security Offerings" (Prompt AI Agent Security; MCP-server policy enforcement), March 23, 2026; Gartner AI-cybersecurity spend forecast (~73.9% CAGR, 2024–2029), January 2026.DISCLAIMER:
Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group (MIQ). MIQ has been paid a fee for Integrated Cyber Solutions (ICS). advertising and digital media from the company directly. There may be 3rd parties who may have shares of ICS, and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ owns shares of ICS which were purchased in the open market, and/or through private placements, and reserve the right to buy and sell, and will sell shares of ICS at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by ICS; this is a paid advertisement, we currently own shares of ICS and will sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
SentinelOne's stock dropped after announcing plans to trim 8% of its full-time workforce to focus on AI and data investments. The cyber firm also issued lackluster guidance for the current quarter and full year.
SentinelOne Inc. (NYSE: S) shares fell nearly 11% on Friday after the cybersecurity company topped earnings estimates but issued softer-than-expected second-quarter revenue guidance and announced a roughly 8% workforce reduction.
The company reported first-quarter fiscal 2027 revenue of $276.7 million, just below the Wall Street consensus of $277.3 million but within its own guidance range.
Adjusted EPS of $0.04 beat the $0.02 analyst estimate.
Annual recurring revenue rose 23% year-over-year to $1.16 billion, slightly above estimates. Net new ARR reached a record $44 million, up 55% year-over-year, marking the fourth consecutive quarter of positive net new ARR growth. Remaining performance obligations grew 30% year-over-year to a record $1.5 billion.
Non-endpoint solutions, including AI, data, and cloud, now represent approximately half of total ARR. AI security ARR nearly doubled sequentially, while the company's Flex offering surpassed $200 million in total contract value in under three quarters since launch.
For the second quarter, SentinelOne guided for revenue of $289 million to $291 million, below the Street's estimate of approximately $292 million. The guidance includes an estimated $25 million restructuring charge tied to the workforce reduction, which is expected to generate approximately $45 million in annualized savings. Full-year non-GAAP EPS guidance of $0.32 to $0.38 bracketed the consensus estimate of $0.34.
Wedbush maintained its Outperform rating and $20 price target, saying the company is "sharpening its operating model" under new CFO Sonalee Parekh and remains well positioned in AI security.
Bank of America was more constructive, upgrading the stock to Buy from Neutral and raising its price target to $20 from $16. The bank called the post-market selloff an attractive entry point, citing durable 20%-plus revenue growth and a clear path to margin expansion, and characterized the conservative guidance as a deliberate reset under new leadership rather than a sign of weakening demand.
